Clinical Trial Update: Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AsiDNA in combination with Olaparib in participants with recurrent solid tumors has completed; the study includes metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer
• Epithelial Ovarian Cancer

Drugs mentioned

• AsiDNA (AsiDNA)
• Olaparib (Olaparib)

Snippet

Sponsor: Valerio Therapeutics | Conditions: Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED